| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1040167140 |
| P356 | DOI | 10.1007/S40265-013-0094-3 |
| P698 | PubMed publication ID | 23861187 |
| P50 | author | Anders Fasth | Q45866509 |
| P2093 | author name string | Jenny Lingman-Framme | |
| P2860 | cites work | The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration | Q21092360 |
| Grading quality of evidence and strength of recommendations | Q24562409 | ||
| Agammaglobulinemia | Q28244575 | ||
| The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy | Q33332528 | ||
| Cerebral sinus thrombosis following IV immunoglobulin therapy of immune thrombocytopenia purpura | Q33394682 | ||
| Subcutaneous immunoglobulin-g replacement therapy with preparations currently available in the United States for intravenous or intramuscular use: reasons and regimens | Q33878939 | ||
| Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology | Q34507918 | ||
| CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. I. THE CHARACTERIZATION OF THE PROTEIN FRACTIONS OF HUMAN PLASMA. | Q35158953 | ||
| Immunoglobulin replacement treatment by rapid subcutaneous infusion | Q35259959 | ||
| Subcutaneous immunoglobulin replacement in primary immunodeficiencies | Q35811020 | ||
| Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency. | Q35959163 | ||
| Immunoglobulin replacement therapy in primary antibody deficiency diseases--maximizing success | Q36043289 | ||
| Long-term survival and late deaths after hematopoietic cell transplantation for primary immunodeficiency diseases and inborn errors of metabolism. | Q36078279 | ||
| Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. | Q36121067 | ||
| Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases | Q36196688 | ||
| Immunodeficiency in childhood | Q36616792 | ||
| Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies | Q36646678 | ||
| Subcutaneous immunoglobulin for patients with antibody deficiency. | Q36804229 | ||
| Consensus on diagnosis and management of primary antibody deficiencies. Consensus Panel for the Diagnosis and Management of Primary Antibody Deficiencies | Q36884511 | ||
| Bioavailability of IgG administered by the subcutaneous route. | Q36927579 | ||
| Human Immunoglobulins for intravenous use and hepatitis C viral transmission | Q36932236 | ||
| Home care use of intravenous and subcutaneous immunoglobulin for primary immunodeficiency in the United States | Q36949416 | ||
| Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency | Q37142890 | ||
| Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century | Q37252276 | ||
| Preparation and use of therapeutic antibodies primarily of human origin. | Q37267852 | ||
| Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes | Q37304914 | ||
| The nurse's role in administration of intravenous immunoglobulin therapy | Q37391277 | ||
| Subcutaneous immunoglobulin: opportunities and outlook | Q37626132 | ||
| Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis | Q37676957 | ||
| Immunoglobulin treatment in primary antibody deficiency | Q37833222 | ||
| Indications and safety of intravenous and subcutaneous immunoglobulin therapy | Q37877259 | ||
| Bringing immunoglobulin knowledge up to date: how should we treat today? | Q37901520 | ||
| Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose | Q37942415 | ||
| Modern management of primary B-cell immunodeficiencies | Q37962045 | ||
| Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases | Q38002601 | ||
| Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis | Q38021422 | ||
| Comparison of American and European practices in the management of patients with primary immunodeficiencies. | Q39607271 | ||
| The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial | Q40598470 | ||
| Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency | Q42237378 | ||
| Case-control study of thromboembolic events associated with IV immunoglobulin | Q43422324 | ||
| Comparison of high-dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases | Q43723349 | ||
| Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies | Q44050973 | ||
| Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs | Q44215065 | ||
| Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion | Q44492893 | ||
| Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. | Q50784030 | ||
| Patients' attitude to subcutaneous immunoglobulin substitution as home therapy. | Q50933791 | ||
| Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. | Q51025072 | ||
| [Subcutaneous gammaglobulin in common variable immunodeficiency. First experience in Spain]. | Q51128632 | ||
| Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. | Q51571051 | ||
| Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin. | Q51894105 | ||
| Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. | Q51936602 | ||
| Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? | Q53067119 | ||
| Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. | Q53176831 | ||
| Subcutaneous immunoglobulins: Alternative for the hypogammaglobulinemic patient? | Q57996314 | ||
| High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease | Q69898445 | ||
| [Economic evaluation of at home subcutaneous and intravenous immunoglobulin substitution] | Q79162953 | ||
| A decade with agammaglobulinemia | Q79358849 | ||
| Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance | Q80853169 | ||
| Immunoglobulin therapy: methods of delivery | Q82007810 | ||
| Human gammaglobulin | Q82099282 | ||
| Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home | Q82287317 | ||
| Primary immunodeficiencies | Q82368673 | ||
| Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease | Q83675646 | ||
| [Immunoglobulins in PID, SID and neurological autoimmune disease] | Q83705004 | ||
| Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study | Q83940736 | ||
| Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease | Q84411545 | ||
| A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously | Q84574325 | ||
| Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies | Q84626781 | ||
| Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency | Q84670379 | ||
| Subcutaneous IgG replacement after pediatric SCT | Q84893771 | ||
| Pharmacoeconomic advantages of subcutaneous versus intravenous immunoglobulin treatment in a Canadian pediatric center | Q87414069 | ||
| P433 | issue | 12 | |
| P304 | page(s) | 1307-1319 | |
| P577 | publication date | 2013-08-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review | |
| P478 | volume | 73 |
| Q38661420 | A cohort of French pediatric patients with primary immunodeficiencies: are patient preferences regarding replacement immunotherapy fulfilled in real-life conditions? |
| Q38548417 | Antibody replacement therapy in primary antibody deficiencies and iatrogenic hypogammaglobulinemia |
| Q89304980 | Biweekly Hizentra® in Primary Immunodeficiency: a Multicenter, Observational Cohort Study (IBIS) |
| Q38266635 | Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. |
| Q33610367 | Disease burden for patients with primary immunodeficiency diseases identified at reference hospitals in Guanajuato, Mexico |
| Q37031111 | Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages". |
| Q33849464 | Health-Related Quality of Life in Adult Patients with Common Variable Immunodeficiency Disorders and Impact of Treatment |
| Q64292734 | Health-Related Quality of Life in Patients with CVID Under Different Schedules of Immunoglobulin Administration: Prospective Multicenter Study |
| Q26784167 | Health-related quality of life in patients with primary immunodeficiency disease |
| Q33692418 | II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies |
| Q38257643 | Immunoglobulin replacement therapy for primary immunodeficiencies |
| Q33417506 | Intravenous and subcutaneous immunoglobulin replacement: a two-way road. Optimizing healthcare quality in patients with primary immunodeficiencies |
| Q33419638 | Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europe |
| Q64118161 | Primary and Secondary Immunodeficiency Diseases in Oncohaematology: Warning Signs, Diagnosis, and Management |
| Q59127411 | Primary immunodeficiency diseases in lung disease: warning signs, diagnosis and management |
| Q48302996 | Quality of Life, Treatment Beliefs, and Treatment Satisfaction in Children Treated for Primary Immunodeficiency with SCIg |
| Q90457449 | Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities |
| Q33695997 | Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients. |
| Q36149327 | Treatment with Hizentra in patients with primary and secondary immunodeficiencies: a real-life, non-interventional trial. |
Search more.